Recent major concern has been focused on the direct effect of locally produced angiotensin II in cardiac tissue on cardiac hypertrophy. We assessed the role of angiotensin II on the development of left ventricular (LV) pressure-overload hypertrophy by using a newly developed angiotensin II receptor antagonist, TCV-116. Weadministered 0.3 mg/kg/day (low dose